Ophthalmology News and Research

RSS

Ophthalmology is the specialized field of medicine that focuses on the health of the eye. It includes the anatomy, physiology and diseases that may affect the eye. Historically, the science of ophthalmology encompassed all aspects of visual function, both in health and in illness. Additionally, ophthalmology also includes animal eyes as ocular function and optic diseases are similar among humans and animals.

Natural killer cells promote induction of dry eye disease: New discovery

If you are one of the millions of people around the world who struggle with dry eye disease, good news is on the way. A new research discovery published in the Journal of Leukocyte Biology offers hope for new drugs that treat the cellular cause of the disease rather than its symptoms.

1 Jun 2011

EURETINA honors Retina Implant founder with Innovation Award in the field of artificial vision

Retina Implant AG today announced that the Company's founder Professor Eberhart Zrenner M.D. was awarded the second prize by The European Society for Retina Specialists.

31 May 2011

Scientists identify new molecular pathway that may combat retinal disease, cancers

Scientists identify in the journal Nature a new molecular pathway used to suppress blood vessel branching in the developing retina - a finding with potential therapeutic value for fighting diseases of the retina and a variety of cancers.

30 May 2011

USC engineers to develop robot vision-based mobility aid for visually impaired people

For the visually impaired, navigating city streets or neighborhoods has constant challenges. And most such people still must rely on a very rudimentary technology-a simple cane-to help them make their way through a complex world.

26 May 2011

New faceshields offer protection to football players with amblyopia

Game-worn football faceshields are more susceptible to breaking when subjected to high-velocity impact than are new faceshields, according to recent research.

24 May 2011

Valeant to acquire Sanitas for EUR314 million

Valeant Pharmaceuticals International, Inc. today announced that it has agreed to acquire AB Sanitas for approximately EUR314 million in cash.

24 May 2011

Wills Eye Institute and Thomas Jefferson University create new vision research center

A new vision research center based in Philadelphia will foster regional, national and global collaborations among a diverse group of exceptional clinicians and researchers working to better diagnose, treat and prevent visual diseases.

21 May 2011

New research contributes to basic biological understanding of how retinas develop

New research at UC Santa Barbara is contributing to the basic biological understanding of how retinas develop. The study is part of the campus's expanding vision research.

21 May 2011

Modified vitamin A drug may help prevent age-related macular degeneration

Slowing down the aggregation or "clumping" of vitamin A in the eye may help prevent vision loss caused by macular degeneration, research from Columbia University Medical Center has found.

19 May 2011

Merck acquires Inspire Pharmaceuticals

Merck, known as MSD outside the United States and Canada, announced today that it is has completed its acquisition of Inspire Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing ophthalmic products, for $5.00 per share in cash.

17 May 2011

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its licensee, Alimera Sciences, Inc., resubmitted a New Drug Application for the investigational drug ILUVIEN for the treatment of diabetic macular edema (DME) to the U.S. Food and Drug Administration (FDA) on May 12, 2011 to address questions raised in the Complete Response Letter (CRL) Alimera received in December 2010.

16 May 2011

Inspire reports net loss of $17.6 million for first quarter 2011

Inspire Pharmaceuticals, Inc. announced today financial results for the first quarter ended March 31, 2011, reporting a net loss of $17.6 million or per common share, as compared to a net loss of $14.8 million, or per common share, for the same period in 2010.

10 May 2011

Mary Ann Liebert's peer-reviewed journal highlights latest developments in ocular gene therapy

Disorders of the eye are excellent targets for gene therapy because the ocular environment is readily accessible, relatively easy to monitor, and sequestered from the rest of the body.

10 May 2011

Kowa presents three K-115 study results against glaucoma at ARVO 2011

Kowa Company Ltd, today announced the results of two clinical studies and a non-clinical study of a drug candidate for glaucoma and ocular hypertension.

10 May 2011

Study shows benefits and safety of pediatric contact lens wear

After ten years of contact lens wear, patients are equally successful wearing contact lenses whether they were first fitted as children or as teenagers, new research shows.

7 May 2011

Research experts to speak at brain tumor educational conference

Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.

5 May 2011

MiMedx introduces AmnioFix Nerve Wrap for use in surgical procedures

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane, announced today the launch of AmnioFix Nerve Wrap, the Company's latest biologic implant processed to offer surgical and healing options for nerve repair.

5 May 2011

SARcode reports encouraging data from SAR 1118 Phase 2 dry eye trial

SARcode Corporation presented data today for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related function as compared to placebo. These data were part of the scientific program of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held in Fort Lauderdale, Florida.

4 May 2011

Retina Implant's second clinical trial initial findings presented at ARVO 2011

Retina Implant AG, a leading developer of subretinal implants for the visually impaired, today announced the presentation of initial findings from their second clinical trial.

3 May 2011

Merck's Phase III study shows efficacy results of tafluprost to treat ocular hypertension

Merck, known as MSD outside the United States and Canada, announced today that new Phase III data showed that patients with open-angle glaucoma or ocular hypertension, who were dosed once-daily with tafluprost, Merck's investigational, preservative-free prostaglandin analogue ophthalmic solution, experienced a reduction in intraocular pressure comparable to patients taking twice-daily preservative-free timolol maleate, a beta-adrenergic antagonist.

3 May 2011